RESEARCH





Health workers' compliance to rapid diagnostic tests (RDTs) to guide malaria treatment: a systematic review and meta-analysis

Alinune N. Kabaghe^{1,2}, Benjamin J. Visser^{2,3*}, Rene Spijker^{4,5}, Kamija S. Phiri¹, Martin P. Grobusch^{2,3} and Michèle van Vugt^{2*}

Abstract

Background: The World Health Organization recommends malaria to be confirmed by either microscopy or a rapid diagnostic test (RDT) before treatment. The correct use of RDTs in resource-limited settings facilitates basing treatment onto a confirmed diagnosis; contributes to speeding up considering a correct alternative diagnosis, and prevents overprescription of anti-malarial drugs, reduces costs and avoids unnecessary exposure to adverse drug effects. This review aims to evaluate health workers' compliance to RDT results and factors contributing to compliance.

Methods: A PROSPERO-registered systematic review was conducted to evaluate health workers' compliance to RDTs in sub-Saharan Africa, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies published up to November 2015 were searched without language restrictions in Medline/Ovid, Embase, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Biosis Previews and the African Index Medicus. The primary outcome was health workers treating patients according to the RDT results obtained.

Results: The literature search identified 474 reports; 14 studies were eligible and included in the quantitative analysis. From the meta-analysis, health workers' overall compliance in terms of initiating treatment or not in accordance with the respective RDT results was 83 % (95 % Cl 80–86 %). Compliance to positive and negative results was 97 % (95 % Cl 94–99 %) and 78 % (95 % Cl 66–89 %), respectively. Community health workers had higher compliance rates to negative test results than clinicians. Patient expectations, work experience, scepticism of results, health workers' cadres and perceived effectiveness of the test, influenced compliance.

Conclusions: With regard to published data, compliance to RDT appears to be generally fair in sub-Saharan Africa; compliance to negative results will need to improve to prevent mismanagement of patients and overprescribing of anti-malarial drugs. Improving diagnostic capacity for other febrile illnesses and developing local evidence-based guidelines may help improve compliance and management of negative RDT results.

Trial registration: CRD42015016151 (PROSPERO)

Keywords: Malaria, Rapid diagnostic test (RDT), Health workers, Sub-Saharan Africa, *Plasmodium falciparum*, Clinical decision making, Adherence, Compliance

DE Amsterdam, The Netherlands

Full list of author information is available at the end of the article



© 2016 Kabaghe et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*}Correspondence: bj.visser@amc.uva.nl; m.vanvugt@amc.uva.nl

² Division of Internal Medicine, Department of Infectious Diseases,


Center of Tropical Medicine and Travel Medicine, Academic Medical

Center, University of Amsterdam, Meibergdreef 9, PO Box 22700, 1100

Background

Plasmodium falciparum malaria is estimated to have caused 528,000 deaths and 163 million clinical episodes in sub-Saharan Africa in 2013 [1]. Early diagnosis and treatment with appropriate anti-malarial drugs can prevent severe illness and lethal outcome [2, 3]. Artemisinin-based combination therapy (ACT) is currently recommended for the treatment of uncomplicated malaria caused by *P. falciparum* [3, 4] and is increasingly used for non-falciparum malaria [5]. Effective case-management of malaria consists of an efficacious treatment, prompt access to treatment and diagnosis, provider compliance to treatment guidelines, and patient adherence to medication [3, 6] (Fig. 1).

Presumptive diagnosis and treatment of malaria based on symptoms leads to over- diagnosis of malaria and missed diagnosis for patients without malaria [7, 8]. The World Health Organization (WHO) recommends that any suspected malaria case in any epidemiological setting should be parasitologically-confirmed by either microscopy or rapid diagnostic test (RDT) before treatment [3]. Lack of trained personnel, equipment [9], and reagents for microscopy in most remote rural areas in Africa [10, 11] with high malaria burden makes the RDT the most practically suitable tool to confirm a malaria diagnosis [12, 13]. RDTs are immunochromatographic test kits which confirm the presence of malaria parasites in suspected patients by detecting one or a combination of the following three Plasmodium antigens: Plasmodium histidine-rich protein (HRP) 2 (pHRP-2) for P. falciparum or a 'pan-specific' aldolase to detect other species, such as P. vivax or Plasmodium lactate dehydrogenase (LDH) variants (pLDH) (with clonality specific to the various Plasmodium species infecting humans) [14, 15].



The use of malaria RDT can reduce over-prescribing of anti-malarial drugs (AMD). Studies have shown that in most endemic countries in sub-Saharan Africa, health workers of different cadres do not comply with malaria RDTs; they prescribe AMDs to patients with RDT negative results [13, 16–18]. This has implications on resources for patient, family members and health system since some drug combinations are relatively expensive [19–21]. Non-compliance to malaria negative results by prescribing AMDs neglects underlying cause of fever and expose patients unnecessarily to adverse effects; underlying infections, such as sepsis, pneumonia and meningitis [22–25], present as malaria clinically but are not routinely investigated [26] and may not be treated [10, 27].

To treat malaria effectively, to reduce costs and avoid unnecessary exposure to drug adverse effects, there is a need to correctly diagnose and comply with malaria treatment guidelines or clinical decision algorithms. Health workers (HWs) need to use the correct treatment based on the RDT results.

This systematic review examines data available on HWs compliance to RDT results in sub-Saharan Africa, and investigates factors associated with compliance to results (HW treating patients according to the RDT result). The primary outcome is the percentage of HWs compliant to overall, positive or negative, test results.

Methods


This systematic review was registered in advance in the International prospective register of systematic reviews (PROSPERO; registration number CRD42015016151) which included pre-specified the objectives and inclusion criteria [28].

An experienced information specialist (RS) conducted a search without language or time restrictions in the online electronic databases Ovid Medline, Ovid Embase, Cochrane Central Register of Controlled Trials, CINAHL Plus with Full Text, African Index Medicus, and African Journals Online (AJOL). The search used both free text words and medical subject headings for 'malaria', 'RDT', 'health worker' and 'compliance'. The search was conducted on 3 March 2015 and updated on 12 November 2015. Studies reporting on malaria suspected patients of any age presenting to HWs of any cadre in sub-Saharan Africa were searched. The intervention was the use of a WHO recommended RDT kit for parasitological confirmation of a malaria diagnosis (a list of WHO recommended RDTs is available online [29]).

Bibliographies of relevant studies retrieved from the studies were checked for additional publications. The search strategy is described in Additional file 1. End-Note X7.4 (Thomson Reuters) was used to manage, deduplicate and screen the references for eligibility. The

inclusion criteria were: studies were conducted in sub-Saharan Africa; RDTs were used to diagnose malaria in symptomatic patients; the RDTs used were WHO-recommended; absolute numbers of RDT result adherence as primary or secondary outcome were reported. Exclusion criteria were: studies using RDT for active case finding and population screening; conference abstracts; no absolute numbers were reported; studies outside sub-Saharan Africa. Eligibility assessment of studies was performed independently in a blinded, standardized way by two reviewers (ANK and BJV). Titles and abstracts were screened first, and the two reviewers screened and selected relevant full-text articles. ANK extracted guantitative data based on the pre-specified criteria into an excel sheet (Additional file 2); factors associated with compliance were also extracted into the same sheet. All the quantitative data was independently checked by BJV. Data extracted included author name, year of publication, place of study, transmission setting, type of RDT, cadre and number of HW, age of patients, number of test results, RDT positives treated and RDT negatives not treated. Both qualitative and quantitative factors were also extracted from included studies which reported them. The risk of bias of studies was not assessed because of the diversity of the study designs included.

The primary outcome measure was proportions in percentage of RDT results with appropriate AMD prescription disaggregated to positive and negative results adherence. Appropriate treatment was defined as AMDs prescribed to RDT positive and AMD not prescribed to RDT negative patients (Fig. 2). Formulae for these calculations are included in Additional file 3. STATA version 13 (StataCorp, College Station, TX, USA) was used to calculate the pooled estimate of proportions appropriately treated overall and negative and positive compliance using random effects. Random effects analysis was



used after an initial fixed effect analysis had I^2 above 50 %, suggesting heterogeneity. Pooled estimates were also stratified by health personnel cadre, age of patients and malaria transmission setting. A qualitative synthesis of factors contributing to compliance was also reported for the included studies.

Results


Study selection

The total number of articles after removing duplicates was 474 (Fig. 3). After screening title and abstracts for eligibility, 75 full-text articles were examined for eligibility; 14 studies were included in the quantitative analysis [7, 16–18, 30–39]. Five of the studies reported on factors associated with compliance to RDT results and were included in the summary of associated factors [7, 17, 30, 31, 36].

There were five study designs (Table 1): one randomized control trial [31], four observational [32–34, 38], four cross-sectional [17, 18, 36, 37], four cluster randomized trials [7, 16, 30, 35] and pre-post intervention study [39]. RDT adherence was a secondary outcome in five out of the 14 studies [17, 31, 35, 37, 39].

Health workers' compliance to malaria results

A pooled meta-analysis using random effects (Fig. 4) for the 14 studies [7, 16–18, 30, 31, 33–40] shows an overall compliance of 83 % (95 % CI 80–86 %); $I^2 = 99.9$ %,



Z = 54.35, p < 0.001. Appropriate malaria treatment based on RDT results (Table 2) was as low as 39.7 % in a Zambian study [38] to as high as 99.9 % in Zanzibar [18]. The pooled meta-analysis result using random effects for RDT positives prescribed AMDs (Fig. 5) was 97 % (95 % CI 94–99 %); $I^2 = 99.2$ %, Z = 37.31, p < 0.001. The proportion of positive RDT results prescribed AMDs ranged from 72.1 to 100 %. 12 studies reported appropriate prescription of AMDs to RDT positive patients above 93 %; six of these studies had 100 % RDT positive compliance (Table 2).

Pooled meta-analysis using random effects for RDT negative patients not prescribed AMDs (Fig. 6) was 78 % $(95 \% \text{ CI } 66-89 \%); I^2 = 99.8 \%, Z = 14.60, p < 0.001$. The proportion of RDT negative patients appropriately not prescribed and AMD was between 19.0–99.9 % (Table 2).

Study setting

Stable malaria

Holoondomic

with seasonal transmission

Five studies [16, 31, 36–38] reported less than 60 % compliance to RDT negative results.

Community health workers (CHWs) had the highest adherence to negative results (Fig. 6) with a random effects pooled proportion of 95 % (95 % CI 92-98 %); $I^2 = 86.4$ %, Z = 23.26, p < 0.001 than clinicians with a pooled proportion of 75 % (95 % CI 58–89 %); $I^2 = 99.8$ %, Z = 11.30, p < 0.001. There were no differences in compliance when stratified by patient age or transmission setting in pooled meta-analyses.

Compliance factors

Number

of HWs

NR

00

HW cadre

Nurses

Clinicians

Study design

Observational

RCT

Six out of the 14 studies included [7, 17, 30, 31, 36, 38] reported quantitative or qualitative assessment of factors associated with compliance to RDT. Uzochokwu et al. [36] reported that HWs adhered to RDT positive results,

Age of study

participants

>6 months

5 voarc

RDT

Paracheck Pf

DaraHIT

Table 1	Characteri	stics of stu	dies included
Authors	Year	Country	Study setting

2010 Tanzania

Burkina Faso

2009

Bisoffi [31]

Macapia [22]


Masanja [33]	2010	Tanzania	Holoendemic	Observational	Clinicians	99	>5 years	ParaHII	10,650
Bottieau [32]	2013	Mozambique	Perennial trans- mission with seasonal peaks	Observational	Clinicians	NR	All	Paracheck Pf; ICT malaria Pf; SD Bioline Pf	1385
Manyando [38]	2014	Zambia	Both low and high trans- mission	Observational	Clinicians	NR	<5 years	ICT malaria Pf	1492
Chinkhumba [37]	2010	Malawi	Stable malaria with sea- sonal peak	Cross sectional	Clinicians and nurses	NR	>5 years	ICT malaria pf; SD Bioline; Paracheck Pf; First Response	1390
Uzochukwu [36]	2011	Nigeria	High transmis- sion	Cross sectional	Clinicians, nurses and CHW	32	All	ICT malaria Pf	280
Mubi [17]	2013	Tanzania	Perennial transmission	Cross sectional	Clinicians and nurses	20	>3 months	NR	105
Shakely [18]	2013	Zanzibar	Low transmis- sion	Cross sectional	Clinicians and nurses	33	All	Paracheck Pf	3889
Batwala [30]	2011	Uganda	Both low and high trans- mission	CRT	Clinical officers and nurses	30	All	Paracheck Pf	44,565
Mukanga [35]	2012	Ghana, Uganda	Seasonal	CRT	CHW	44	4–59 months	Paracheck Pf; ICT malaria Pf	1559
Mbacham [<mark>16</mark>]	2014	Cameroon	NR	CRT	Clinicians	198	All	SD Bioline	1194
Bastiaens [39]	2011	Tanzania	NR	Before and after	Clinical officers	NR	Below 10 year olds	ICT malaria Pf; Paracheck Pf	501
Mbonye [7]	2015	Uganda	Perennial transmission	CRT	DSV	10	All	First response	8073
Mukanga [<mark>34</mark>]	2011	Uganda	High transmis- sion	Observational	CHW	14	Under 5 years	NR	182

CHW community health worker, CRT cluster randomized trial, DSV drug shop vendor, NR Not reported, RCT randomized control trial

Sample size

1050

10.650



as they believed they were more reliable in confirming a malaria diagnosis than presumptive diagnosis or microscopy. Bisoffi et al. [31] compared prescribing behaviour of HWs in the dry compared to rainy seasons and reported improved RDT negative results compliance during the dry season; alternative diagnoses were also made in the dry than the rainy season.

Manyando et al. [38] reported no association between prescribing of AMD to negative RDTs in children under

five, and fever in a Zambian study. There was also no association between community health worker (CHW) or socio-demographic characteristics and classification of malaria based on RDT in a bivariate analysis in Uganda [34]. In one study though, 70 % (14/20) of the respondents (HW) believed that RDTs gave inaccurate/false negative results for malaria [17]. Persistence of symptoms and patient pressure and demand were other factors reported to contribute to inappropriate AMD prescription in RDT

Study design	Authors	Country	Health personnel cadre	Appropriate treatment (%)	Positives treated (%)	Negatives not treated (%)
RCT	Bisoffi	Burkina Faso	Nurses	60.7	97.7	19.0
Observational	Masanja	Tanzania	Clinicians	95.9	95.8	96.0
	Bottiaeu ^a	Mozambique	Clinicians	93.4	95.1	92.8
	Mukanga	Uganda	CHW	97.8	98.6	95.2
	Manyando	Zambia	Clinicians	39.7	93.9	31.4
Cross sectional	Chinkhumba	Malawi	Clinicians and nurses	86.9	98.0	57.9
	Uzochukwu	Nigeria	Clinicians, nurses and CHW	60.0	100.0	25.9
	Mubi	Tanzania	Clinicians and nurses	90.5	100.0	86.5
	Shakely	Zanzibar	Clinicians and nurses	99.9	100.0	99.9
CRT	Batwala	Uganda	Clinical officers and nurses	88.5	100.0	76.6
	Mukanga ^b	Ghana	CHW	99.5	100.0	96.7
	Mukanga ^b	Uganda	CHW	99.0	99.9	92.4
	Mbacham ^c	Cameroon	Clinicians	56.1	72.1	48.1
	Mbacham ^d	Cameroon	Clinicians	70.8	72.9	69.4
	Mbonye	Uganda	DSV	98.8	99.0	98.5
Before and after	Bastiaens	Tanzania	Clinical officers	90.4	100.0	90.0

Table 2 Appropriate treatment overall, RDT positive and RDT negative results

CHW community health worker, DSV drug shop vendors

^a Excludes missing data

^b Excludes Burkina Faso results

^c Basic training

^d Enhanced training

negative cases [7, 17, 41]. HWs would end up prescribing AMDs in these cases to satisfy patients and maintain their reputation. Some HW reported that RDT negative patients improved when they were prescribed AMDs.

Discussion

This is the first systematic review and meta-analysis evaluating the proportion of health workers' compliance with RDT results. Overall the compliance is fair. However, it also confirms that compliance to RDT negative results compared to positive results was generally low among HWs.

Diagnostic accuracy of RDT for both falciparum and non-falciparum malaria is high [14, 15]; sensitivity of up to 99.5 % and specificity of up to 90.6 % compared to microscopy for *P. falciparum* [14]. Community health workers can appropriately diagnose and treat malaria using RDT in resource limited settings [13]. The use of RDT to guide treatment reduces AMD prescription especially where health workers adhere to results [42].

The results show a high proportion of HWs prescribe appropriate treatment based on RDT results. A proportion of patients still remain over- or under-treated, despite policy change of administering ACT to parasitological confirmed cases only. Approximately 17 % of RDT negative patients are inappropriately prescribed AMDs. This estimate, extrapolated to sub-Saharan Africa means hundreds of thousands of patients are inappropriately diagnosed for malaria and prescribed AMD drugs unnecessarily; unnecessary (=incorrect) AMD prescription leads to drug wastage, unnecessary exposure to drug adverse effects and an increased risk of drug resistance development for current AMDs [43]. Where underlying infection is not treated, the patient's illness prolongs and worsens; the patient or guardian makes multiple visits to seek health services, lose productivity time or income and leads to school absenteeism for school-going children [21] leading to a vicious cycle of poverty and malaria [44].

Lower cadres of HW showed more compliance to RDT results than trained HWs. The high adherence is likely due to trust in RDT result for confirming malaria diagnosis. Trained HWs on the other hand may trust clinical symptoms and past experience more than RDT result [17, 45].

Factors associated with HW compliance from qualitative studies include knowledge of alternative diagnosis, fever during the dry season and a trust in RDT result [30, 31, 46]. Trust may be increased by improving diagnostic capacity for other common febrile illnesses, and by developing evidence informed guidelines for treatment of

Clinicians Bestiers 2011 Bestiers 2011 Bottleau 2013 Whiteham 2014 Bottleau 2013 Whiteham 2014 Bottleau 2013 Bottleau (1/2 = 98.6%, p = 0.00) 1.00 (0.81, 1.00) 4.97 6.75 6.85 6.97 (0.82, 0.27) Nurses Bestiers 2019 Bottleau 2010 Mischam 20140 Subtoal (1/2 = 98.6%, p = 0.00) 0.88 (0.97, 0.99) 6.60 Ofmicing and nurses Orbital (1/2 = 96.6%, p = 0.00) 0.88 (0.97, 0.99) 6.60 Ofmicing and nurses Bestier 2019 0.98 (0.97, 0.99) 6.60 Ofmicing and nurses Bestier 2010 0.98 (0.97, 0.99) 6.60 Ofwarbar Bostleau (1/2 = 64.5%, p = 0.11) 0.98 (0.97, 0.99) 6.60 OSV Micrye 0.99 (0.98, 0.99) 6.73 OSV Micrye 0.99 (0.98, 1.00) 17.59 OSV Micrye 0.99 (0.98, 1.00) 1.92 Dividing 100 (0.91, 100) 6.93 6.93 OSV Micrye 0.97 (0.94, 0.99) 100.00 OSV Micrye 0.97 (0.94, 0.99) 100.00 OSV Micrye 0.00 0.97 (0.94, 0.99) 100.00 Originicians, nurses and CHW 0.00 0.00 9.165% Nurses Clinicians, nurses and CHW 0.00 0.00 9.165% Nurses Clinicians, nurses and CHW 0.00 0.00 9.165%	Study				ES (95%	CI)	% Weight
Barwala 2011 0.00 (0.00) 6.75 Maryando 2014 0.00 (0.00) 6.75 Mascham 2014a 0.00 (0.00) 6.73 Mascham 2015 0.00 (0.00) 6.73 Mascham 2016 0.00 (0.00) 6.73 Mascham 2017 0.30 (0.00) 6.75 Mascham 2018 0.00 (0.00) 6.75 Mascham 2010 0.00 (0.00) 6.75 Mascham 2013 0.00 (0.00) 6.75 Subtoal (Y2 = 54.5%, p = 0.11) 0.09 (0.99, 0.09) 6.73 DSV 0.09 (0.99, 0.00) 7.5 1 Mascham 2012 0.00 (0.91, 1.00) 6.55 Subtoal (Y2 = 95.6%, p = 0.00) 0.99 (0.99, 0.99) 6.73 Orinicians, nurses and CHW 1.00 (0.98, 1.00) 5.93 Uzochukou 2011 1.00 (0.98, 1.00) 5.93 Mascham 2012 0.00<							
Bottaeu 2013							
Maryando 2014 0.96 (0.95, 0.67) 6.34 Mascham 2014 0.96 (0.95, 0.66) 6.73 Mascham 2014a 0.96 (0.95, 0.67) 6.54 Subtolal (V2 = 99.6%, p = 0.00) 0.98 (0.97, 0.98) 6.65 Nursee 0.98 (0.97, 0.99) 6.66 Clinicians and nurses 0.99 (0.99, 0.99) 6.73 Obstotial (V2 = 64.5%, p = 0.11) 0.99 (0.99, 0.99) 6.73 Disv 0.99 (0.99, 0.99) 6.73 Machang 2011 0.99 (0.99, 0.99) 6.73 Machang 2012 1.00 (0.98, 1.00) 1.94 Mochya 0.99 (0.99, 0.99) 6.73 Machang 2011 1.00 (0.98, 1.00) 1.94 Machang 2012 1.00 (0.98, 1.00) 1.94 Orecall (P2 = 85.8%, p = 0.00) 0.97 (0.94, 0.99) 100.00 Overall (P2 = 91.9%							
Maccham 2014a 0.72 (0.87, 0.78) 6.54 Subtolal (IV2 = 99.6%, p = 0.00) 0.38 (0.96, 0.99) 6.60 Clinicians and nurses 0.38 (0.97, 0.99) 6.66 Clinicians and nurses 0.38 (0.97, 0.99) 6.66 Clinicians and nurses 0.38 (0.97, 0.99) 6.66 Clinicians and nurses 0.39 (0.92, 0.99) 6.73 Clinicians and nurses 0.39 (0.92, 0.99) 6.73 Clinicians nurses 0.39 (0.92, 0.99) 6.73 Mixanga 2012 0.99 (0.92, 0.99) 6.73 Mixanga 2012 0.09 (0.99, 0.90) 6.73 Output 0.99 (0.99, 0.90) 6.73 Clinicians, nurses and CHW 0.00 (0.98, 1.00) 19.42 Ulinicians, nurses and CHW 0.97 (0.94, 0.99) 100.00 Uzcentukwu 2011 1.00 (0.98, 1.00) 5.93 Murses . 0.11 54.45% Clinicians and nurses 4.39 2 0.11 Vizcentukwu 2011 0.00 (0.98, 1.00) 1.00 (0.98, 1.00) Verrel (V2 = 99.16%, p = 0.00) 0.00 9.55% Clinicians and nurses 4.39 2 0.11<	Manyando 2014				0.94 (0.9	0, 0.97)	6.34
Mbacham 2014b $0.73 (0.89, 0.77)$ 6.58 Subtract $0.33 (0.83, 0.99)$ 6.56 Olinicians and nurses $0.88 (0.97, 0.99)$ 6.66 Olinicians and nurses $0.88 (0.97, 0.99)$ 6.66 Olinicians and nurses $0.98 (0.97, 0.99)$ 6.66 Olinicians and nurses $0.98 (0.97, 0.99)$ 6.66 Olinicians and nurses $0.98 (0.97, 0.99)$ 6.67 Subtract $0.98 (0.97, 0.99)$ 6.67 Subtract $0.99 (0.98, 1.00)$ 1.756 DSV $0.99 (0.98, 1.00)$ 1.756 Mukanga 2011 $0.99 (0.98, 1.00)$ 1.53 Mukanga 2012 $0.99 (0.98, 1.00)$ 6.56 Subtract $0.98 (0.97, 0.99)$ 6.56 Olinicians, nurses and CHW $1.00 (0.96, 1.00)$ 5.93 Mukanga 2012 $1.00 (0.96, 1.00)$ 5.93 Mukanga 2012 0.00 $0.97 (0.94, 0.99)$ 10.00 Overail (P2 = 99.16%, p = 0.00) $0.97 (0.94, 0.99)$ 10.00 Overail (P2 = 99.16%, p = 0.00) $0.97 (0.94, 0.99)$ 10.00 Nurses $1.709.23$							
Nurses Bisoff 2009 0.98 (0.96, 0.99) 6.60 Olinicians and nurses Olinicians 2010 Mukenga 2013 Stakely 2013 Stakely 2013 Distrikely 2013 Distrikely 2013 Distrikely 2013 Distrikely 2013 Distrikely 2011 Mukenga 2012i Mukenga 2012i 				_			
Bisoffi 2009 0.98 (0.86, 0.99) 6.60 Clinicians and nurses 0.98 (0.97, 0.99) 6.60 Clinicians and nurses 0.99 (0.97, 0.99) 6.60 DisV 100 (0.97, 0.09) 6.60 Subtable (P2 = 54.5%, p = 0.11) 0.99 (0.98, 1.00) 4.79 DSV Mbonye 0.99 (0.98, 0.99) 6.13 OHW Mukanga 2012 0.99 (0.98, 0.99) 6.19 Mukanga 2012 0.99 (0.98, 1.00) 4.56 Subtable (P2 = 80.5%, p = 0.00) 0.96 (0.92, 0.99) 6.19 Uzochukwu 2011 1.00 (0.98, 1.00) 19.42 Olinicians, nursea and CHW 1.00 (0.98, 1.00) 19.42 Uzochukwu 2011 1.00 (0.96, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Overall (P2 = 99.16%, p = 0.00): 0.97 (0.94, 0.99) 100.00 Virses 0 0 . . Clinicians and nurses 4.39 2 0.11 54.45% CHW 14.10 2 0.00 95.82% DSV . 0 . . <	Subtotal (I^2 = 99.6%, p	= 0.00)		\sim	0.93 (0.8	3, 0.99)	43.76
Chinkhumba 2010 Muki2013 Shakeky 2013 Shakeky 2013 Subtotal ($P2 = 54.5\%$, p = 0.11) DSV Mbonye CHW Mukanga 2012 Mukanga 2012 Mukan				I	0.98 (0.9	6, 0.99)	6.60
Mubi 2013 1.00 (0.89, 1.00) 4.79 Shakely 2013 Subtotal ($N^2 = 54.5\%$, p = 0.11) 0.99 (0.98, 1.00) 17.56 DSV 0.99 (0.99, 0.99) 6.73 CHW Mukanga 2011 0.96 (0.92, 0.99) 6.19 Mukanga 2012 0.96 (0.99, 1.00) 6.65 Mukanga 2012C 0.96 (0.99, 1.00) 6.65 Mukanga 2012C 0.97 (0.94, 0.99) 100.00 Mukanga 2012C 0.97 (0.94, 0.99) 100.00 Mukanga 2012C 1.00 (0.96, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Overall ($N^2 = 99.16\%$, p = 0.00); 0.97 (0.94, 0.99) 100.00 Virals ($N^2 = 99.16\%$, p = 0.00); 0.97 (0.94, 0.99) 100.00 Virals ($N^2 = 99.16\%$, p = 0.00); 0.97 (0.94, 0.99) 100.00 Overall ($N^2 = 99.16\%$, p = 0.00; 0.97 (0.94, 0.99) 100.00 Subtolar ($N^2 = 99.16\%$, p = 0.00; 0.97 (0.94, 0.99) 100.00 Overall ($N^2 = 99.16\%$, p = 0.00; 0.97 (0.94, 0.99) 100.00 Overall ($N^2 = 99.16\%$, p = 0.00; 0.11 54.45% CHW 14.10 2 0.00<	Clinicians and nurses						
Shakely 2013 1.00 (0.97, 1.00) 6.10 Subblail ($P2 = 54.5\%$, $p = 0.11$) 0.99 (0.98, 1.00) 17.56 DSV 0.99 (0.98, 0.99) 6.73 Mbonye 0.99 (0.92, 0.99) 6.19 Mukanga 2012 1.00 (0.97, 1.00) 6.16 Mukanga 2012 1.00 (0.98, 1.00) 6.53 Subtolal ($P2 = 85.8\%$, $p = 0.00$) 0.99 (0.92, 0.99) 6.53 Clinicians, nurses and CHW 1.00 (0.98, 1.00) 5.93 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Verail ($P2 = 90.16\%$, $p = 0.000$ 0.97 (0.94, 0.99) 100.00 Clinicians and nurses 1.39 0.11 54.45% CHW 14.10 2 0	Chinkhumba 2010						
Subtolal ($P2 = 54.5\%, p = 0.11$) DSV Mbonye CHW Mukanga 20121 Mukanga 20121 Mukanga 20121 Clinicians, nurses and CHW Uzochukwu 2011 Heterogeneity between groups: $p = 0.000$ Overall ($P2 = 95.8\%, p = 0.00$) Clinicians and nurses 4.39 2 0.11 5.43 Murses Clinicians and nurses 4.39 2 0.11 5.445% CHW Clinicians, nurses and CHW Uzochukwu 2011 100 (0.96, 1.00) $5.93Heterogeneity between groups: p = 0.000Overall (P2 = 99.16\%, p = 0.000;100 (0.99, 0.99)$ $100.00100 (0.96, 1.00)$ $5.93100 (0.99, 0.99)$ $100.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ $0.000.97 (0.94, 0.99)$ 0.000							
Mbonye 0.99 (0.99, 0.99) 6.73 CHW Mukanga 2012 0.96 (0.92, 0.99) 6.19 Mukanga 2012 1.00 (0.98, 1.00) 6.58 Subtotal ($P2 = 85.8\%$, p = 0.00) 0.97 (0.94, 0.99) 100 (0.98, 1.00) Clinicians, nurses and CHW 1.00 (0.98, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Overall ($P2 = 99.16\%$, p = 0.00): 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Overall ($P2 = 99.16\%$, p = 0.00): 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Overall ($P2 = 99.16\%$, p = 0.00); 0.97 (0.94, 0.99) 100.00 Murses 0.59 . . Clinicians and nurses 4.39 2 0.11 54.45% CHW 14.10 2 0.00 85.82% DSV . 0 . . Overall 1789.95 15 0.00 99.16% Random: Test for heterogeneity between sub-groups . . . <td>Subtotal (I^2 = 54.5%, p</td> <td>= 0.11)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Subtotal (I^2 = 54.5%, p	= 0.11)					
Mukanga 2011 0.60 (0.32, 0.99) 6.19 Mukanga 2012ci 1.00 (0.39, 1.00) 6.59 Mukanga 2012di 1.00 (0.39, 1.00) 6.65 Subtotal ($l^{1/2} = 85.8\%$, p = 0.00) 1.00 (0.39, 1.00) 5.93 Clinicians, nurses and CHW 1.00 (0.39, 1.00) 5.93 Uzochukwu 2011 1.00 (0.39, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.37 (0.94, 0.99) 100.00 Overail ($l^{1/2} = 99.19\%$, p = 0.00); 0.37 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000 0.37 (0.94, 0.99) 100.00 Overail ($l^{1/2} = 99.19\%$, p = 0.00); 0.37 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000 0.37 (0.94, 0.99) 100.00 Out and the p = 0.001 1.00 (0.96, 1.00) 5.93 Mukanga 2012 1.11 54.45% 0.11 54.45% Clinicians and nurses 4.39 2 0.11 54.45% CHW 14.10 2 0.00 85.82% DSV 0 0 0 0 0 Overall 1789.95 15 0.00 99.16% <					0.99 (0.9	9, 0.99)	6.73
Mukanga 2012c 1.00 (0.99, 1.00) 6.58 Mukanga 2012d 1.00 (0.99, 1.00) 6.65 Subtotal ($^{12} = 85.8\%$, p = 0.00) 1.00 (0.98, 1.00) 1.942 Clinicians, nurses and CHW 1.00 (0.96, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.009 Overall ($^{12} = 99.16\%$, p = 0.00): 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Verall ($^{12} = 99.16\%$, p = 0.00): 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Mukanga 2012 1.00 (0.96, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Uzochukwu 2011 10 2.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.00 0.97 (0.94, 0.99) 100.00 Uzochukwu 2011 10 2.97 (0.94, 0.99) 100.00 Mukanga 2012 10 1.00 (0.96, 1.00) 5.93 Subtoal (12 (1.97, 0.97, 0.94, 0.99) 100.00 100.00 Uzochukwu 2011 10 1.97, 0.94, 0.99 100.00					0.96.00	2 () 99)	6 19
Subtotal ($l^{12} = 85.8\%$, p = 0.00) I 100 (0.98, 1.00) 19.42 Clinicians, nurses and CHW I 100 (0.96, 1.00) 5.93 Heterogeneity between groups: p = 0.000 0.97 (0.94, 0.99) 100.00 Overall ($l^{12} = 99.16\%$, p = 0.00); 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000; 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000; 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000; 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000; 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000; 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.000; 0.97 (0.94, 0.99) 100.00 Heterogeneity between groups: p = 0.00; 0.000 99.65% Nurses 1709.23 6 0.00 99.65% Nurses 0.11 54.45% 0.11 54.45% CHW 14.10 2 0.00 85.82% DSV 0 . . . Overall 1789.95 15 0.00 99.16% Random: Test for hete	Mukanga 2012c				1.00 (0.9	9, 1.00)	6.58
Clinicians, nurses and CHW Uzochukwu 20111.00 (0.96, 1.00)5.93Heterogeneity between groups: $p = 0.000$ Overall ($1^{\circ}2 = 99.16\%$, $p = 0.000$);0.97 (0.94, 0.99)100.00Image: 100 (0.96, 1.00)5.93Image: 100 (0.97, 0.94, 0.99)100.00Image: 100 (0.97, 0.9		a = 0.00					
Uzochukwu 2011 1.00 (0.96, 1.00) 5.93 Heterogeneity between groups: $p = 0.000$ Overall ($P2 = 99.16\%$, $p = 0.000$): 0.97 (0.94, 0.99) 100.00 0 .25 .5 .75 1 Heterogeneity Degrees of statistic p l^{2**} Clinicians 1709.23 6 0.00 99.65% Nurses . 0 . . Clinicians and nurses 4.39 2 0.11 54.45% CHW 14.10 2 0.00 85.82% DSV . 0 . . Overall 1789.95 15 0.00 99.16% Random: Test for heterogeneity between sub-groups . . . 2961.53 5 0.00 . . ** I ² the variation in estimate attributable to heterogeneity . . . Clinicians and nurses Z = 38.35 p = 0.00 . . OVerall 2 = 38.07 p = 0.00 . . Clinicians and nurses Z = 38.07 p = 0.00 . .						-,,	
Overall ($l^{1/2} = 99.16\%, p = 0.00$): Image: 0.07 (0.94, 0.99) 100.00 Image: 0.08 (0.07, 0.97,		HW			1 .00 (0.9	6, 1.00)	5.93
Overall (I*2 = 99.16%, p = 0.00): Image: transmission of the transmission of the transmission of		0.000					
Image: constraint of the second statisticDegrees of freedomP l^{2**} Clinicians1709.2360.0099.65%Nurses.0.Clinicians and nurses4.3920.11SV.0.Clinicians, nurses and CHW.0.Derail1789.95150.00Overall1789.95150.00Porall1789.9550.00Part of the terogeneity between sub-groups2961.5352961.5350.00*** I ² the variation in estimate attributable to heterogeneityClinicians and nursesZ = 16.66 $p = 0.00$ NursesZ = 65.74 $p = 0.00$ Clinicians and nursesZ = 38.35 $p = 0.00$ Clinicians and nursesZ = 38.07 $p = 0.00$ CHWZ = 38.07 $p = 0.00$ CSVZ = 204.99 $p = 0.00$				<	0.97 (0.9	4, 0.99)	100.00
025 $5 - 75$ Proportion1Heterogeneity statisticDegrees of freedomp l^{2**} Clinicians1709.2360.0099.65%Nurses0000Clinicians and nurses4.3920.1154.45%CHW14.1020.0085.82%DSV0000DsV000Clinicians, nurses and CHW000Overall1789.95150.0099.16%Random: Test for heterogeneity between sub-groups 2961.5350.00** l² the variation in estimate attributable to heterogeneity50.00Clinicians NursesZ= 16.66 $p = 0.00$ NursesZ= 38.35 $p = 0.00$ Clinicians and nursesZ= 38.35 $p = 0.00$ Clinicians and nursesZ= 38.07 $p = 0.00$ CHWZ= 38.07 $p = 0.00$ DSVZ= 204.99 $p = 0.00$							
statisticfreedomP l^{2**} Clinicians1709.2360.0099.65%Nurses.0Clinicians and nurses4.3920.1154.45%CHW14.1020.0085.82%DSV.0Clinicians, nurses and CHW0Overall1789.95150.0099.16%Random: Test for heterogeneity between sub-groups 2961.5350.00*** l² the variation in estimate attributable to heterogeneity50.00NursesZ = 16.66p = 0.00.NursesZ = 65.74p = 0.00.Clinicians and nursesZ = 38.35p = 0.00CHWZ = 38.07p = 0.00.DSVZ = 204.99p = 0.00.		•		i	I 1		
statisticfreedomP l^{2**} Clinicians1709.2360.0099.65%Nurses.0Clinicians and nurses4.3920.1154.45%CHW14.1020.0085.82%DSV.0Clinicians, nurses and CHW0Overall1789.95150.0099.16%Random: Test for heterogeneity between sub-groups 2961.5350.00*** l² the variation in estimate attributable to heterogeneity50.00NursesZ = 16.66p = 0.00.NursesZ = 38.35p = 0.00.Clinicians and nursesZ = 38.35p = 0.00CHWZ = 38.07p = 0.00.DSVZ = 204.99p = 0.00		Hetero	ogeneity Dea	rees of			
Nurses 0 . Clinicians and nurses 4.39 2 0.11 54.45% CHW 14.10 2 0.00 85.82% DSV . 0 . . Clinicians, nurses and CHW 0 . . . Overall 1789.95 15 0.00 99.16% Random: Test for heterogeneity between sub-groups 2961.53 5 0.00 ** I ² the variation in estimate attributable to heterogeneity 5 0.00 Nurses Z= 16.66 p = 0.00 . Nurses Z= 65.74 p = 0.00 . Clinicians and nurses Z= 38.35 p = 0.00 . CHW Z= 38.07 p = 0.00 . DSV Z= 204.99 p = 0.00 .					Ρ	l ^{2**}	
Clinicians and nurses4.3920.1154.45%CHW14.1020.0085.82%DSV.0DSV.0Clinicians, nurses and CHW.0Overall1789.95150.0099.16%Random: Test for heterogeneity between sub-groups 2961.53 50.00** I² the variation in estimate attributable to heterogeneity50.00NursesZ= 16.66p = 0.00.NursesZ= 65.74p = 0.00.Clinicians and nursesZ= 38.35p = 0.00CHWZ= 38.07p = 0.00.DSVZ= 204.99p = 0.00.		170	9.23		0.00	99.65%	
CHW 14.10 2 0.00 85.82% DSV . 0 . . Clinicians, nurses and CHW 0 . . Overall 1789.95 15 0.00 99.16% Random: Test for heterogeneity between sub-groups . . . 2961.53 5 0.00 . . K 1 ² the variation in estimate attributable to heterogeneity 5 0.00 . Nurses Z= 16.66 p = 0.00 . . . Clinicians Z= 16.66 p = 0.00 . . . Clinicians Z= 38.35 p = 0.00 . . . Clinicians and nurses Z= 38.07 p = 0.00 . . . DSV Z= 204.99 p = 0.00 						•	
DSV0.Clinicians, nurses and CHW0.Overall1789.95150.00Overall2961.5350.00Random: Test for heterogeneity between sub-groups 2961.53 50.00** I² the variation in estimate attributable to heterogeneity 2961.53 50.00NursesZ = 16.66p = 0.00p = 0.00NursesZ = 65.74p = 0.00Clinicians and nursesZ = 38.35p = 0.00CHWZ = 38.07p = 0.00DSVZ = 204.99p = 0.00							
Clinicians, nurses and CHW0Overall1789.95150.0099.16%Random: Test for heterogeneity between sub-groups 2961.5350.00** l² the variation in estimate attributable to heterogeneity50.00CliniciansZ= 16.66p = 0.00NursesZ= 65.74p = 0.00Clinicians and nursesZ= 38.35p = 0.00CHWZ= 38.07p = 0.00DSVZ= 204.99p = 0.00		1	4.10	2	0.00	85.82%	
Overall1789.95150.0099.16%Random: Test for heterogeneity between sub-groups 2961.53 50.00** I² the variation in estimate attributable to heterogeneity50.00CliniciansZ= 16.66p = 0.00NursesZ= 65.74p = 0.00Clinicians and nursesZ= 38.35p = 0.00CHWZ= 38.07p = 0.00DSVZ= 204.99p = 0.00				0.		•	
Random: Test for heterogeneity between sub-groups 2961.53 5 0.00** I² the variation in estimate attributable to heterogeneityCliniciansZ= 16.66NursesZ= 65.74Z= 65.74p = 0.00Clinicians and nursesZ= 38.35CHWZ= 38.07DSVZ= 204.99DSVZ= 204.99DSVZ= 204.99Clinicians		W		0.			
2961.5350.00** l² the variation in estimate attributable to heterogeneityClinicians $Z = 16.66$ $p = 0.00$ Nurses $Z = 65.74$ $p = 0.00$ Clinicians and nurses $Z = 38.35$ $p = 0.00$ CHW $Z = 38.07$ $p = 0.00$ DSV $Z = 204.99$ $p = 0.00$	Overall	178	9.95	15	0.00	99.16%	
** l^2 the variation in estimate attributable to heterogeneity Clinicians Z= 16.66 p = 0.00 Nurses Z= 65.74 p = 0.00 Clinicians and nurses Z= 38.35 p = 0.00 CHW Z= 38.07 p = 0.00 DSV Z= 204.99 p = 0.00	Random: Test for heterc	ogeneity betweer	n sub-groups				
Clinicians $Z= 16.66$ $p = 0.00$ Nurses $Z= 65.74$ $p = 0.00$ Clinicians and nurses $Z= 38.35$ $p = 0.00$ CHW $Z= 38.07$ $p = 0.00$ DSV $Z= 204.99$ $p = 0.00$					0.00		
Nurses $Z = 65.74$ $p = 0.00$ Clinicians and nurses $Z = 38.35$ $p = 0.00$ CHW $Z = 38.07$ $p = 0.00$ DSV $Z = 204.99$ $p = 0.00$	** I ² the variation in esti	imate attributabl	e to heterogen	eity			
Clinicians and nurses Z= 38.35 p = 0.00 CHW Z= 38.07 p = 0.00 DSV Z= 204.99 p = 0.00			-				
CHW Z= 38.07 p = 0.00 DSV Z= 204.99 p = 0.00		Z= 65.74	•				
DSV Z= 204.99 p = 0.00	Nurses			00			
	Nurses	Z= 38.35	p = 0.				
Clinicians, nurses and CHW $Z = 28.22$ $p = 0.00$	Nurses Clinicians and nurses		-	00			
	Nurses Clinicians and nurses CHW	Z= 38.07	p = 0.				
Overall Z= 37.31 p = 0.00	Nurses Clinicians and nurses CHW DSV	Z= 38.07 Z= 204.99	p = 0. p = 0.	00			

Study					ES (95% CI)	% Weight
Clinicians				-	0.00 (0.07, 0.00)	6.00
Bastiaens Batwala 2				-	0.90 (0.87, 0.93) 0.77 (0.76, 0.77)	6.30 6.34
Bottiaeu 2	2013			-	0.93 (0.91, 0.94)	6.32
Manyando		-		_	0.31 (0.29, 0.34)	6.33
Masanja 2 Mbacham		-	- i	-	0.96 (0.95, 0.97) 0.48 (0.45, 0.52)	6.34 6.32
Mbacham		0.00)	-	>	0.69 (0.66, 0.73) 0.75 (0.58, 0.89)	6.32 44.26
Nurses	(i 2 00i0/0; p	0.00)			0110 (0100) 0100)	11120
Bisoffi 20	09	-			0.19 (0.16, 0.23)	6.30
	and nurses					
Chinkhum Multi 2011				_	0.58 (0.53, 0.63)	6.29
Mubi 2013 Shakely 2			1	ı	0.86 (0.77, 0.93) 1.00 (1.00, 1.00)	6.09 6.34
	(l^2 = 99.7%, p =	0.00)		>	0.87 (0.41, 1.00)	18.72
DSV Mbonye				-	0.98 (0.98, 0.99)	6.34
CHW Mukanga	2011				0.98 (0.87, 1.00)	5.90
Mukanga	2012c				0.97 (0.91, 0.99)	6.14
Mukanga Subtotal	2012d (I^2 = 8.1%, p =	0.34)		-	0.92 (0.86, 0.96) 0.95 (0.92, 0.98)	6.18 18.22
Clinicians Uzochukv	, nurses and CH' wu 2011	w			0.26 (0.18, 0.35)	6.17
	neity between gro					
Overall (I	l^2 = 99.82%, p =			>	0.78 (0.66, 0.89)	100.00
	0	.25	I I .5 .75 Proportion		1	
			Degrees			
		Heterogeneity statistic	of freedom P		12**	
Clinicians						
Nurses		3520.34	6	0.00	99.83%	
Clinicians and nu	Ircoc	663.27	0 2	0.00	2007 002	
	11262			0.00	99.70%	
CHW		2.18	2	0.34	8.12%	
DSV		•	0		•	
Clinicians, nurses	s and CHW		0			
Overall Dandam: Tast fo	* hoto:	8554.66	15	0.00	99.82%	
Random: Test fo	neterogene	eity between sub 1549	groups 5	0.00		
**I2 the variatio	n in estimate	e attributable to h		0.00		
	Significant	e test(s) of ES=0				
Clinicians	Jigimicali	Z = 11.30	p = 0.00			
Nurses		Z= 48.75	p = 0.00 p = 0.00			
Clinicians and nu	irses	Z= 46.75 Z= 4.50	p = 0.00 p = 0.00			
		Z= 38.38	p = 0.00 p = 0.00			
CHW/		2- 30.30	p – 0.00			
CHW		7-161 69	n = 0.00			
CHW DSV Clinicians, nurses	a and CLIM	Z= 161.68 Z= 10.18	p = 0.00 p = 0.00			

symptomatic RDT negative patients. Such guidelines may not apply in non-endemic areas and therefore should be specific to particular settings.

Knowledge of alternative diagnosis is related to the level of training and experience of HW [47]. HWs reported they likely made alternative diagnosis during the dry season when malaria transmission is perceived lower in febrile children with negative RDT result compared to the wet season when transmission peaks. For febrile patients, alternative diagnoses were made during the dry season while more patients were treated for malaria during the wet season in one study [31].

Qualitative studies report pressure on prescribers to satisfy patient expectations as one factor, which contributes to non-compliance of RDT negative results [44, 48]. Chandler et al. [49] reported patient psychology and prescriber reputation as other factors influencing non-compliance to of HWs to negative RDT.

Interventions to improve compliance have not been successful, although they led to a decrease in ACT prescriptions in particular. Some HWs prescribed a non-recommended AMD in malaria negative patients [16, 50].

In cases of patients demanding AMDs, community sensitisation on RDTs was reported to improve patient satisfaction [7]. At facility level, involvement of patient in discussing malaria results also improved patient satisfaction and reduced patient demand for AMDs [51].

Notably, few studies were available which quantified HW's compliance to malaria RDT results, and even less studies investigated the factors contributing to compliance. Understanding these factors can help design effective strategies to improve compliance of anti-malarial drugs. Chandler et al. [49] describe a systematic method of designing an intervention in Tanzania; formative research would be key in designing such an intervention. However, interventions are context-specific and may not be applicable to all settings, and for all HWs. It is essential to investigate factors contributing to non-compliance in specific cadres and settings, exploring impact in a context specific manner before designing and implementing interventions.

Although ideal for rural areas in Africa, RDT kits inherently are not 100 % sensitive and specific [14, 42]. Clinically diagnosed malaria and positive malaria test may be due to other underlying causes of the fever [27]. Crump et al. reported only 1.6 % of 820 patients with fever or history of fever actually had malaria infection in a Tanzanian prospective cohort study; bacterial and fungal bloodstream infections were responsible for 9.8 and 2.9 % of the fever, respectively. Resource limited settings lack diagnostic equipment and capacity for some diseases. Diagnostic accuracy of RDTs can be affected further by low and extremely high parasite densities [52, 53], patient-intrinsic factors such as rheumatoid factor positivity [54], user factors such as result interpretation and performance of the test, and environmental storage conditions including high temperatures. It is, therefore, possible, though infrequent, for malaria-infected patients to have a false positive (leading to not-indicated treatment) or more importantly, false negative result, and hence miss malaria treatment if WHO malaria treatment guidelines are followed. A more robust and highly specific test may be useful to rule out malaria. False positives, where malaria parasitaemia is not the cause of the illness (in endemic areas) lead to neglecting of other febrile illnesses.

Multidisciplinary research to explore, measure and design interventions for increasing compliance to RDT results in different settings in Africa need to be conducted. More innovation in diagnosis of common febrile illnesses in malaria endemic regions needs to be available. There is sparse data on prevalence of other nonmalaria febrile illnesses in most malaria endemic regions of Africa.

The meta-analysis may have overestimated compliance: studies evaluating diagnostic tests generally report higher compliance when assessed in the study setting compared to a non-study setting. Most studies reported higher compliance to positive results compared to negative results.

A limitation for the results in the review is that risk of bias and publication bias were not assessed for the studies included; the quality of evidence therefore cannot be reported.

Conclusion

HWs compliance to RDT is fair; compliance to positive RDT results is generally higher compared to negative RDT results. Over-treatment of malaria is still a major problem in sub-Saharan Africa. Both HW and patient factors contribute to inappropriate prescribing of AMDs to RDT negative patients; interventions to improve compliance should target both patients and HWs. Treatment guidelines should be developed for other causes of fever informed by local context and research. Multidisciplinary research will improve compliance of HWs to RDT results.

Additional files

Additional file 1. Search strategy. Additional file 2. Data extraction form. Additional file 3. Formulae for appropriate treatment.

Abbreviations

ACT: artemisinin-based combination therapy; AL: artemether-lumefantrine; AMC: Academic Medical Center; AMDs: anti-malarial drugs; CERMEL: Centre

de Recherches Médicales de Lambaréné; CI: confidence interval; CHW: community health worker; HW: health worker; RDT: rapid diagnostic test; WHO: World Health Organization.

Authors' contributions

ANK, KSP and MVV conceived the review. ANK and BJV developed the study design and the outline of the report. ANK and RS searched the scientific literature. ANK and BJV screened the search results. ANK prepared the first draft of the report and performed the statistical analyses. BJV checked all the quantitative data. BJV, RS, KSP, MGP and MVV contributed to the outline of the report. All authors contributed to the writing, and approved of the final manuscript version. All authors read and approved the final manuscript.

Author details

¹ Public Health Department, College of Medicine, Private Bag 360, Blantyre, Malawi. ² Division of Internal Medicine, Department of Infectious Diseases, Center of Tropical Medicine and Travel Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, PO Box 22700, 1100 DE Amsterdam, The Netherlands. ³ Centre de Recherches de Médicales de Lambaréné (CERMEL), Albert Schweitzer Hospital, Lambaréné, Gabon. ⁴ Medical Library, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁵ Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Acknowledgements

This study was supported by the Dioraphte Foundation, The Netherlands. We thank the reviewer for his/her thorough and excellent review.

Competing interests

The authors declare that they have no competing interests.

Received: 12 January 2016 Accepted: 5 March 2016 Published online: 15 March 2016

References

- WHO. World malaria report: 2014. Geneva: World Health Organization; 2014 (2015).
- Grobusch MP, Kremsner PG. Uncomplicated malaria. Curr Top Microbiol Immunol. 2005;295:83–104.
- 3. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
- Visser BJ, van Vugt M, Grobusch MP. Malaria: an update on current chemotherapy. Expert Opin Pharmacother. 2014;15:2219–54.
- Visser BJ, Wieten RW, Kroon D, Nagel IM, Belard S, van Vugt M, et al. Efficacy and safety of artemisinin combination therapy (ACT) for nonfalciparum malaria: a systematic review. Malar J. 2014;13:463.
- malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011;8:e1000397.
- Mbonye AK, Magnussen P, Lal S, Hansen KS, Cundill B, Chandler C, et al. A cluster randomised trial introducing rapid diagnostic tests into registered drug shops in Uganda: impact on appropriate treatment of malaria. PLoS One. 2015;10:e0129545.
- Steinhardt LC, Chinkhumba J, Wolkon A, Luka M, Luhanga M, Sande J, et al. Patient-, health worker-, and health facility-level determinants of correct malaria case management at publicly funded health facilities in Malawi: results from a nationally representative health facility survey. Malar J. 2014;13:64.
- Wiseman V, Ezeoke O, Nwala E, Mangham LJ, Cundill B, Enemuo J, et al. A cost-effectiveness analysis of provider and community interventions to improve the treatment of uncomplicated malaria in Nigeria: study protocol for a randomized controlled trial. Trials. 2012;13:81.
- Nankabirwa J, Zurovac D, Njogu JN, Rwakimari JB, Counihan H, Snow RW, et al. Malaria misdiagnosis in Uganda–implications for policy change. Malar J. 2009;8:66.
- 11. Kahama-Maro J, D'Acremont V, Mtasiwa D, Genton B, Lengeler C. Low quality of routine microscopy for malaria at different levels of the health system in Dar es Salaam. Malar J. 2011;10:332.

- Ruizendaal E, Dierickx S, Peeters Grietens K, Schallig HD, Pagnoni F, Mens PF. Success or failure of critical steps in community case management of malaria with rapid diagnostic tests: a systematic review. Malar J. 2014;13:229.
- Abba K, Deeks JJ, Olliaro P, Naing CM, Jackson SM, Takwoingi Y, et al. Rapid diagnostic tests for diagnosing uncomplicated *P. falciparum* malaria in endemic countries. Cochrane Database Syst Rev. 2011;7:CD008122.
- Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, et al. Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or *Plasmodium vivax* malaria in endemic countries. Cochrane Database Syst Rev. 2014;12:CD011431.
- Mbacham WF, Mangham-Jefferies L, Cundill B, Achonduh OA, Chandler CIR, Ambebila JN, et al. Basic or enhanced clinician training to improve adherence to malaria treatment guidelines: a cluster-randomised trial in two areas of Cameroon. Lancet Glob Health. 2014;2:e346–58.
- Mubi M, Kakoko D, Ngasala B, Premji Z, Peterson S, Bjorkman A, et al. Malaria diagnosis and treatment practices following introduction of rapid diagnostic tests in Kibaha district, coast region, Tanzania. Malar J. 2013;12:293.
- Shakely D, Elfving K, Aydin-Schmidt B, Msellem MI, Morris U, Omar R, et al. The usefulness of rapid diagnostic tests in the new context of low malaria transmission in Zanzibar. PLoS One. 2013;8:e72912.
- Shillcutt SD, Morel CM, Coleman PG, Mills AJ, Goodman CA. Costeffectiveness of malaria diagnosis in sub-Saharan Africa: the role of rapid diagnostic tests in rural settings with high *Plasmodium falciparum* transmission. Geneva: World Health Organization; 2006. p. 173. http:// www.who.int/malaria/publications/atoz/malaria-subsaharan-africa/en/. Accessed 3 Mar 2016.
- Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, Whitty CJ, et al. Costeffectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ. 2008;86:101–10.
- 21. Amexo M, Tolhurst R, Barnish G, Bates I. Malaria misdiagnosis: effects on the poor and vulnerable. Lancet. 2004;364:1896–8.
- Akpede GO, Sykes RM. Malaria with bacteraemia in acutely febrile preschool children without localizing signs: coincidence or association/ complication? J Trop Med Hyg. 1993;96:146–50.
- Berkley JA, Maitland K, Mwangi I, Ngetsa C, Mwarumba S, Lowe BS, et al. Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ. 2005;330:995.
- Molyneux E, Walsh A, Phiri A, Molyneux M. Acute bacterial meningitis in children admitted to the Queen Elizabeth Central Hospital, Blantyre, Malawi in 1996–97. Trop Med Int Health. 1998;3:610–8.
- English M, Punt J, Mwangi I, McHugh K, Marsh K. Clinical overlap between malaria and severe pneumonia in Africa children in hospital. Trans R Soc Trop Med Hyg. 1996;90:658–62.
- Nichols C, Cruz Espinoza LM, von Kalckreuth V, Aaby P, Ahmed El Tayeb M, Ali M, et al. Bloodstream infections and frequency of pretreatment associated with age and hospitalization status in sub-Saharan Africa. Clin Infect Dis. 2015;61(Suppl 4):S372–9.
- 27. Koram KA, Molyneux ME. When Is "Malaria" Malaria? The different burdens of malaria infection, malaria disease, and malaria-like illnesses. Am J Trop Med Hyg. 2007;77:1–5.
- Health workers' compliance to Rapid Diagnostic Tests (RDTs) to guide malaria treatment: protocol for systematic review and meta-analysis. http://www.crd.york.ac.uk/PROSPERO/DisplayPDF. php?ID=CRD42015016151. Accessed 3 Mar 2016.
- Information note on recommended selection criteria for procurement of malaria rapid diagnostic tests. http://www.who.int/malaria/publications/ atoz/rdt_selection_criteria/en/. Accessed 3 Mar 2015.
- Batwala V, Magnussen P, Nuwaha F. Comparative feasibility of implementing rapid diagnostic test and microscopy for parasitological diagnosis of malaria in Uganda. Malar J. 2011;10:373.
- Bisoffi Z, Sirima BS, Angheben A, Lodesani C, Gobbi F, Tinto H, et al. Rapid malaria diagnostic tests vs. clinical management of malaria in rural Burkina Faso: safety and effect on clinical decisions. A randomized trial. Trop Med Int Health. 2009;14:491–8.
- Bottieau E, Gillet P, De Weggheleire A, Scheirlinck A, Stokx J, Mosse CDD, et al. Treatment practices in patients with suspected malaria in provincial hospital of Tete, Mozambique. Tran R Soc Trop Med Hyg. 2013;107:176–82.

- Masanja MI, McMorrow M, Kahigwa E, Kachur SP, McElroy PD. Health workers' use of malaria rapid diagnostic tests (RDTS) to guide clinical decision making in rural dispensaries, Tanzania. Am J Trop Med Hyg. 2010;83:1238–41.
- 34. Mukanga D, Babirye R, Peterson S, Pariyo GW, Ojiambo G, Tibenderana JK, et al. Can lay community health workers be trained to use diagnostics to distinguish and treat malaria and pneumonia in children? Lessons from rural Uganda. Trop Med Int Health. 2011;16:1234–42.
- 35. Mukanga D, Tiono AB, Anyorigiya T, Kallander K, Konate AT, Oduro AR, et al. Integrated community case management of fever in children under five using rapid diagnostic tests and respiratory rate counting: a multicountry cluster randomized trial. Am J Trop Med Hyg. 2012;87:21–9.
- Uzochukwu BSC, Onwujekwe E, Ezuma NN, Ezeoke OP, Ajuba MO, Sibeudu FT. Improving rational treatment of malaria: perceptions and influence of RDTs on prescribing behaviour of health workers in Southeast Nigeria. PLoS One. 2011;6:e14627.
- Chinkhumba J, Skarbinski J, Chilima B, Campbell C, Ewing V, San Joaquin M, et al. Comparative field performance and adherence to test results of four malaria rapid diagnostic tests among febrile patients more than five years of age in Blantyre, Malawi. Malar J. 2010;9:209.
- 38. Manyando C, Njunju EM, Chileshe J, Siziya S, Shiff C. Rapid diagnostic tests for malaria and health workers' adherence to test results at health facilities in Zambia. Malar J. 2014;13:166.
- Bastiaens GJ, Schaftenaar E, Ndaro A, Keuter M, Bousema T, Shekalaghe SA. Malaria diagnostic testing and treatment practices in three different *Plasmodium falciparum* transmission settings in Tanzania: before and after a government policy change. Malar J. 2011;10:76.
- Briggs M, Chinkhumba J, Bauleni A, Sande J, Luhanga M, Dodoli W, et al. Nationwide health facility survey of severe malaria case management-Malawi 2012. ASTMH 62nd Annual Meeting, November 13–17, Washington, DC, Poster 211; 2013.
- Brasseur P, Badiane M, Cisse M, Vaillant M, Olliaro PL. Changes in malaria prevalence and health provider's behavior towards fever with the introduction of act and RDT at peripheral health centre level in Southwestern Senegal (2000–2011). ASTMH 61st Annual Meeting, November 11–15, Atlanta. Poster 900: 2012.
- Odaga J, Sinclair D, Lokong JA, Donegan S, Hopkins H, Garner P. Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings. Cochrane Database Syst Rev. 2014;4:CD008998.

- Bloland PB. Drug resistance in malaria. Geneva: World Health Organization; 2001. p. 15. http://www.who.int/csr/resources/publications/drugresist/malaria.pdf?ua=1. Accessed 3 Mar 2016.
- 44. Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415:680–5.
- 45. Diggle E, Asgary R, Gore-Langton G, Nahashon E, Mungai J, Harrison R, et al. Perceptions of malaria and acceptance of rapid diagnostic tests and related treatment practises among community members and health care providers in Greater Garissa, North Eastern Province, Kenya. Malar J. 2014;13:502.
- Bisoffi Z, Gobbi F, Van Den Ende J. Rapid diagnostic tests for malaria. BMJ. 2014;348:3846.
- Selemani M, Masanja IM, Kajungu D, Amuri M, Njozi M, Khatib RA, et al. Health worker factors associated with prescribing of artemisinin combination therapy for uncomplicated malaria in rural Tanzania. Malar J. 2013;12:334.
- Achonduh OA, Mbacham WF, Mangham-Jefferies L, Cundill B, Chandler C, Pamen-Ngako J, et al. Designing and implementing interventions to change clinicians' practice in the management of uncomplicated malaria: lessons from Cameroon. Malar J. 2014;13:204.
- Chandler CI, Meta J, Ponzo C, Nasuwa F, Kessy J, Mbakilwa H, et al. The development of effective behaviour change interventions to support the use of malaria rapid diagnostic tests by Tanzanian clinicians. Implement Sci. 2014;9:83.
- Skarbinski J, Ouma PO, Causer LM, Kariuki SK, Barnwell JW, Alaii JA, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg. 2009;80:919–26.
- Chandler CI, Mwangi R, Mbakilwa H, Olomi R, Whitty CJ, Reyburn H. Malaria overdiagnosis: is patient pressure the problem? Health Policy Plan. 2008;23:170–8.
- 52. Gillet P, Mori M, Van Esbroeck M, Van den Ende J, Jacobs J. Assessment of the prozone effect in malaria rapid diagnostic tests. Malar J. 2009;8:271.
- Gillet P, Scheirlinck A, Stokx J, De Weggheleire A, Chauque HS, Canhanga OD, et al. Prozone in malaria rapid diagnostics tests: how many cases are missed? Malar J. 2011;10:166.
- Grobusch MP, Alpermann U, Schwenke S, Jelinek T, Warhurst DC. Falsepositive rapid tests for malaria in patients with rheumatoid factor. Lancet. 1999;353:297.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

